Novo Nordisk AS’s investigational GLP-1 agonist semaglutide demonstrated a significant reduction in major adverse cardiovascular events in the SUSTAIN-6 cardiovascular outcomes trial, which will strengthen its new drug application for the therapy and supplement future negotiations with pricing regulators.
The full data from the SUSTAIN-6 non-inferiority study were presented on Sept. 16 to rapturous applause at the European Association...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
